Pfizer has declared that its respiratory syncytial virus (RSV) vaccine, Abrysvo, has demonstrated a robust immune response in a late-stage clinical study
Pfizer has declared that its respiratory syncytial virus (RSV) vaccine, Abrysvo, has demonstrated a robust immune response in a late-stage clinical study